Definiens and BioImage Pen High-Content Screening Alliance

genomeweb
360dx

Definiens and BioImage Pen High-Content Screening Alliance

Dec 06, 2004

NEW YORK, Dec. 6 (GenomeWeb News) - Definiens and BioImage will co-market their products for high-content cell-based screening assays, and co-develop applications in this area, the companies said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

NanoString Technologies Prices $103.5M Common Stock Offering
Interpace Diagnostics Posts 32 Percent Increase in Q4 Revenues
Anatolian Hunter-Gatherers Adopted Farming Practices, Ancient DNA Study Suggests
Glaucoma Diagnostic Targeted by Mannin Research, McMaster University Collaboration
NanoString Technologies Plans Common Stock Offering
Oxford Biodynamics Joins UK Prostate Cancer Screening Trial

The Scan

Push for Predictive Genetic Tests

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Gene-Editing Registry Proposed

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Sneaking Out of the Lab

Vox writes that lab mishaps involving pathogens are quite common.

This Week in Genome Biology

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Menu